Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world study on discontinuation strategies after MRD negativity in multiple myeloma patients

View Full Paper
Ask AI
Bookmark
Share

Authors

JLJuan Li

Discussion

Loading...

Member takes

Overview

Observational analysis explores MRD-guided treatment cessation, suggesting lower MRD resurgence risk with prolonged negativity in multiple myeloma patients.

Key Points

  • Patients achieving MRD negativity early and sustaining it for 24 months are at lower risk for MRD resurgence post-discontinuation.
  • Among 25 patients analyzed, the median time to MRD resurgence was 24.7 months, indicating variability in outcomes.
  • High-risk cytogenetics trends toward increased recurrence risk, emphasizing the need for careful patient selection.
  • This supports the potential for personalized, time-limited treatment strategies in multiple myeloma based on MRD status.

Cite This Study

Juan Li (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d7c4https://doi.org/10.1182/blood-2025-2209
View Full Paper
Ask AI
Bookmark
Share